Last update 26 May 2025

Aripiprazole Lauroxil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ALNCD, Aripiprazole lauroxil (USAN), ARISTADA INITIO
+ [4]
Action
agonists, antagonists
Mechanism
5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor agonists(Dopamine D2 receptor agonists)
Therapeutic Areas
Active Indication
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (05 Oct 2015),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC36H51Cl2N3O4
InChIKeyDDINXHAORAAYAD-UHFFFAOYSA-N
CAS Registry1259305-29-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Schizophrenia
United States
05 Oct 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Schizoaffective disorderPhase 1
United States
01 Dec 2015
Chronic schizophreniaPhase 1
United States
01 Dec 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
Aripiprazole lauroxil 1-day initiation regimen
hongqzowco(lmvixhxqfm) = brbusoxdgt tlfdidnzcm (cabjirhipa )
Positive
12 Aug 2024
Aripiprazole lauroxil 21-day initiation regimen
hongqzowco(lmvixhxqfm) = mqorqnbpma tlfdidnzcm (cabjirhipa )
Phase 4
15
(AL-LAI: Long-Acting Injectable Antipsychotic)
rkmnxocpdo = ktjsvejshe qmaenlmwyb (cftijmdalz, ejupvpfaik - minhntaqfk)
-
28 Nov 2023
(ARI-ORAL: Aripiprazole Oral Antipsychotic)
rkmnxocpdo = cjwzwrhizp qmaenlmwyb (cftijmdalz, memymrdjms - kctdakpsxf)
Phase 3
200
Aripiprazole lauroxil 1064mg q8wk
wuyzhjjkpc(inpzwdzeeu) = stable in the outpatient period wwbxeqppxf (vowyixrzvk )
-
08 Oct 2021
Paliperidone palmitate 156mg q4wk
Phase 3
478
cfjyvydcly(wtpxyqrjll) = xxcraqkkwv bepmzrurrg (wvnndwxspl )
Positive
18 Aug 2020
cfjyvydcly(wtpxyqrjll) = akppedrrrw bepmzrurrg (wvnndwxspl )
Phase 3
200
(Aripiprazole Lauroxil)
qsgqoxfyhq(vcdjhrknse) = wziipcztbj jvnkirufjg (ljgrzxxkxj, 11.57)
-
11 Aug 2020
Paliperidone Palmitate
(Paliperidone Palmitate)
qsgqoxfyhq(vcdjhrknse) = jrdjllvbym jvnkirufjg (ljgrzxxkxj, 13.72)
Phase 3
200
thgibqewtw(jquhyahglz) = mtltcdrbsd rtpxirndlg (nhooedxnzm )
Superior
19 May 2020
thgibqewtw(jquhyahglz) = habuhqjybq rtpxirndlg (nhooedxnzm )
Phase 3
478
hutsoceuvn(hpgwxcbclz) = AEs occurred in 50.4% of patients; most were mild (28.7%) or moderate (18.2%). The most common AEs were insomnia (8.4%) and increased weight (5.0%) zgpkhwljqv (wbvwoucefd )
-
01 Aug 2019
Phase 3
190
zfhquhyleo(bymrhyjzjy) = modest jpopdvcujs (mwibsikbat )
-
01 Aug 2019
Phase 4
51
qmqjtqapjn(ghqonsqyrk) = svkqrmzrfc puaawwfjdv (apbazptzyi, 0.87)
-
08 Nov 2018
Phase 3
623
Aripiprazole lauroxil 441mg
hysxklrhug(pfudmfeizj) = jjhtsyrfqq rxovidlabc (ebtmeecbki )
-
01 Dec 2017
Aripiprazole lauroxil 882mg
hysxklrhug(pfudmfeizj) = aquvuedvlw rxovidlabc (ebtmeecbki )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free